Oramed Pharmaceuticals Inc.

Major Shareholding Notification • Mar 1, 2019

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

* 1. Name and Address of Reporting Person Hasleton Mark Daniel					2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
					ORMP ]									Director			10% Owner
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 02/26/2019									X	Officer (give title below)		Other (specify below)
HI-TECH PARK 2/4 GIVAT-RAM														VP Business Development
P.O. BOX 39098					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)
(Street)														X Form filed by One Reporting Person
	JERUSALEM L3 91390												Form filed by More than One Reporting Person
(City)		(State)	(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)					2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. and 5) 8)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4			Securities Beneficially Owned	5. Amount of	(D) or	6. Ownership Form: Direct Indirect (I)	7. Nature of Indirect Beneficial Ownership
								V	Amount		(A) or (D)	Price	Following Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		(Instr. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed if any	Execution Date, (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

Stock Option (right to buy)

1. The Stock Option will vest in 4 equal installments of 5,625 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022.

Code V (A) (D)

/s/ Mark Hasleton 02/28/2019

Amount or Number of Shares

** Signature of Reporting Person Date

(Instr. 4)

Stock 22,500 \$⁰ 22,500 ^D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

\$3.16 02/26/2019 A 22,500 (1) 02/26/2029

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

(Instr. 3, 4 and 5)

Date Exercisable

Expiration Date Title

Common